Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Recurrent High Grade Glioma
NCT00004868Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2000
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of semaxanib in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligoastrocytoma (AOA), malignant astrocytoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)anaplastic oligoastrocytoma (AOA)malignant astrocytoma
Beyond the preview
Go deeper on NCT00004868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004868.